{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:01:44Z","timestamp":1787893304080,"version":"build-2784847793"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014942","name":"Novartis Gene Therapies Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014942","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","award":["41,42"],"award-info":[{"award-number":["41,42"]}],"id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ejpn-journal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ejpn.2024.08.006","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T09:03:35Z","timestamp":1724749415000},"page":"18-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Outcomes for patients in the RESTORE registry with spinal muscular atrophy and four or more SMN2 gene copies treated with onasemnogene abeparvovec"],"prefix":"10.1016","volume":"53","author":[{"given":"Eduardo F.","family":"Tizzano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Quijano-Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Servais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3450-762X","authenticated-orcid":false,"given":"Julie A.","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7255-6276","authenticated-orcid":false,"given":"Sharon","family":"Aharoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpita","family":"Lakhotia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Finkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janbernd","family":"Kirschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darryl C.","family":"De Vivo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayoko","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dheeraj","family":"Raju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Benguerba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Dabbous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayla","family":"Mumneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra P.","family":"Reyna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Faulkner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejpn.2024.08.006_bib1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ejhg.2011.134","article-title":"Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens","volume":"20","author":"Sugarman","year":"2012","journal-title":"Eur. J. Hum. Genet."},{"issue":"4","key":"10.1016\/j.ejpn.2024.08.006_bib2","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","article-title":"Spinal muscular atrophy","volume":"33","author":"Kolb","year":"2015","journal-title":"Neurol. Clin."},{"issue":"9","key":"10.1016\/j.ejpn.2024.08.006_bib3","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/ejhg.2010.54","article-title":"Molecular characterization of SMN copy number derived from carrier screening and from core families with SMA in a Chinese population","volume":"18","author":"Sheng-Yuan","year":"2010","journal-title":"Eur. J. Hum. Genet."},{"issue":"7","key":"10.1016\/j.ejpn.2024.08.006_bib4","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.3390\/jcm9072222","article-title":"New treatments in spinal muscular atrophy: positive results and new challenges","volume":"9","author":"Messina","year":"2020","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.ejpn.2024.08.006_bib5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.ejpn.2024.08.006_bib6","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1007\/s13311-014-0293-y","article-title":"Spinal muscular atrophy: journeying from bench to bedside","volume":"11","author":"Awano","year":"2014","journal-title":"Neurotherapeutics"},{"issue":"11","key":"10.1016\/j.ejpn.2024.08.006_bib7","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","article-title":"A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy","volume":"96","author":"Lorson","year":"1999","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"2","key":"10.1016\/j.ejpn.2024.08.006_bib8","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.24497","article-title":"Spinal muscular atrophy: diagnosis and management in a new therapeutic era","volume":"51","author":"Arnold","year":"2015","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.ejpn.2024.08.006_bib9","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ana.25101","article-title":"Natural history of infantile-onset spinal muscular atrophy","volume":"82","author":"Kolb","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejpn.2024.08.006_bib10","author":"Cure"},{"issue":"7","key":"10.1016\/j.ejpn.2024.08.006_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201004","article-title":"Prospective and longitudinal study of patients with type 2 and 3 spinal muscular atrophy: baseline data. NatHis-SMA study","volume":"13","author":"Chabanon","year":"2018","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.ejpn.2024.08.006_bib12","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1093\/brain\/awac125","article-title":"Pre-symptomatic spinal muscular atrophy: a proposed nosology","volume":"145","author":"Finkel","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.ejpn.2024.08.006_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.earlhumdev.2019.104851","article-title":"Treating neonatal spinal muscular atrophy: a 21st century success story?","volume":"138","author":"Tizzano","year":"2019","journal-title":"Early Hum. Dev."},{"issue":"3","key":"10.1016\/j.ejpn.2024.08.006_bib14","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"Calucho","year":"2018","journal-title":"Neuromuscul. Disord."},{"issue":"16","key":"10.1016\/j.ejpn.2024.08.006_bib15","doi-asserted-by":"crossref","first-page":"9029","DOI":"10.3390\/ijms22169029","article-title":"The importance of digging into the genetics of SMN genes in the therapeutic scenario of spinal muscular atrophy","volume":"22","author":"Costa-Roger","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.ejpn.2024.08.006_bib16","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","article-title":"SMA Care group. Diagnosis and management of spinal muscular atrophy: Part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics","volume":"28","author":"Finkel","year":"2018","journal-title":"Neuromuscul. Disord."},{"issue":"2","key":"10.1016\/j.ejpn.2024.08.006_bib17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"SMA Care Group. Diagnosis and management of spinal muscular atrophy: Part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ejpn.2024.08.006_bib18","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3233\/JND-221510","article-title":"Newborn screening for SMA - can a wait-and-see strategy be responsibly justified in patients with four SMN2 copies?","volume":"9","author":"Blaschek","year":"2022","journal-title":"J. Neuromuscul. Dis."},{"issue":"2","key":"10.1016\/j.ejpn.2024.08.006_bib19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/JND-200475","article-title":"Infants diagnosed with spinal muscular atrophy and 4 SMN2 copies through newborn screening - opportunity or burden?","volume":"7","author":"M\u00fcller-Felber","year":"2020","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ejpn.2024.08.006_bib20","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/338627","article-title":"Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy","volume":"70","author":"Feldkotter","year":"2002","journal-title":"Am. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.ejpn.2024.08.006_bib21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00415-005-0912-y","article-title":"SMN2 copy number predicts acute or chronic spinal muscular atrophy but does not account for intrafamilial variability in siblings","volume":"253","author":"Cusc\u00f3","year":"2006","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.ejpn.2024.08.006_bib22","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.ejhg.5200957","article-title":"Inverse correlation between SMN1 and SMN2 copy numbers: evidence for gene conversion from SMN2 to SMN1","volume":"11","author":"Ogino","year":"2003","journal-title":"Eur. J. Hum. Genet."},{"issue":"6","key":"10.1016\/j.ejpn.2024.08.006_bib23","doi-asserted-by":"crossref","first-page":"e530","DOI":"10.1212\/NXG.0000000000000530","article-title":"Practical guidelines to manage discordant situations of SMN2 copy number in patients with spinal muscular atrophy","volume":"6","author":"Cusc\u00f3","year":"2020","journal-title":"Neurol Genet"},{"issue":"1","key":"10.1016\/j.ejpn.2024.08.006_bib24","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.nmd.2019.11.002","article-title":"244th ENMC International Workshop: newborn screening in spinal muscular atrophy May 10\u201312, 2019, Hoofdorp, The Netherlands","volume":"30","author":"Dangouloff","year":"2020","journal-title":"Neuromuscul. Disord."},{"issue":"8","key":"10.1016\/j.ejpn.2024.08.006_bib25","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1212\/WNL.0000000000006026","article-title":"Precious SMA natural history data: a benchmark to measure future treatment successes","volume":"91","author":"Darras","year":"2018","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.ejpn.2024.08.006_bib26","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1002\/ana.26788","article-title":"Clinical phenotype of pediatric and adult patients with spinal muscular atrophy with four SMN2 copies: are they really all stable?","volume":"94","author":"Ricci","year":"2023","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.ejpn.2024.08.006_bib27","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ana.26358","article-title":"The 4-copy conundrum in the treatment of infants with spinal muscular atrophy","volume":"91","author":"Deng","year":"2022","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.ejpn.2024.08.006_bib28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3233\/JND-180304","article-title":"Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening","volume":"5","author":"Glascock","year":"2018","journal-title":"J. Neuromuscul. Dis."},{"issue":"7","key":"10.1016\/j.ejpn.2024.08.006_bib29","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/genes14071377","article-title":"Spinal muscular atrophy treatment in patients identified by newborn screening\u2014a systematic review","volume":"14","author":"Aragon-Gawinska","year":"2023","journal-title":"Genes"},{"issue":"18","key":"10.1016\/j.ejpn.2024.08.006_bib30","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ejpn.2024.08.006_bib31","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4103\/ijabmr.IJABMR_190_19","article-title":"Onasemnogene abeparvovec for spinal muscular atrophy: the costlier drug ever","volume":"9","author":"Mahajan","year":"2019","journal-title":"Int J Appl Basic Med Res."},{"issue":"11","key":"10.1016\/j.ejpn.2024.08.006_bib32","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul. Disord."},{"issue":"4","key":"10.1016\/j.ejpn.2024.08.006_bib33","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.ejpn.2024.08.006_bib34","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Mercuri","year":"2021","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.ejpn.2024.08.006_bib35","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurol."},{"issue":"7","key":"10.1016\/j.ejpn.2024.08.006_bib36","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.ejpn.2024.08.006_bib37","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","article-title":"Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ejpn.2024.08.006_bib38","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3233\/JND-230122","article-title":"Real-world outcomes in patients with spinal muscular atrophy treated with onasemnogene abeparvovec monotherapy: findings from the RESTORE registry","volume":"11","author":"Servais","year":"2024","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ejpn.2024.08.006_bib39","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3233\/JND-190451","article-title":"RESTORE: a prospective multinational registry of patients with genetically confirmed spinal muscular atrophy \u2013 rationale and study design","volume":"7","author":"Finkel","year":"2020","journal-title":"J. Neuromuscul. Dis."},{"issue":"11","key":"10.1016\/j.ejpn.2024.08.006_bib40","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1002\/acn3.51889","article-title":"Combination disease-modifying treatment in spinal muscular atrophy: a proposed classification","volume":"10","author":"Proud","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.ejpn.2024.08.006_bib41","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1177\/15648265040251S104","article-title":"The WHO Multicentre Growth Reference Study: planning, study design, and methodology","volume":"25","author":"de Onis","year":"2004","journal-title":"Food Nutr. Bull."},{"key":"10.1016\/j.ejpn.2024.08.006_bib42","first-page":"86","article-title":"WHO Motor Development Study: windows of achievement for six gross motor development milestones","volume":"450","year":"2006","journal-title":"Acta Paediatr. Suppl."},{"issue":"2","key":"10.1016\/j.ejpn.2024.08.006_bib43","first-page":"180","article-title":"Bayley Scales of infant and Toddler development \u2013 Third edition","volume":"25","author":"Bayley","year":"2006","journal-title":"San Antonio, TX: Harcourt Assessment. J Psychoeduc Assess"},{"key":"10.1016\/j.ejpn.2024.08.006_bib44","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"Finkel","year":"2014","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ejpn.2024.08.006_bib45","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jpeds.2012.05.067","article-title":"Pathophysiological insights derived by natural history and motor function of spinal muscular atrophy","volume":"162","author":"Farrar","year":"2013","journal-title":"J. Pediatr."},{"issue":"3","key":"10.1016\/j.ejpn.2024.08.006_bib46","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3233\/JND-190403","article-title":"AVXS-101 (onasemnogene abeparvovec) for SMA1: comparative study with a prospective natural history cohort","volume":"6","author":"Al-Zaidy","year":"2019","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ejpn.2024.08.006_bib47","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-024-12188-5","article-title":"5qSMA: standardised retrospective natural history assessment in 268 patients with four copies of SMN2","author":"Vill","year":"2024","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.ejpn.2024.08.006_bib48","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3233\/JND-190468","article-title":"Revised recommendations for the treatment of infants diagnosed with spinal muscular atrophy via newborn screening who have 4 copies of SMN2","volume":"7","author":"Glascock","year":"2020","journal-title":"J. Neuromuscul. Dis."},{"issue":"3","key":"10.1016\/j.ejpn.2024.08.006_bib49","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00439-019-01983-0","article-title":"Complete sequencing of the SMN2 gene in SMA patients detects SMN gene deletion junctions and variants in SMN2 that modify the SMA phenotype","volume":"138","author":"Ruhno","year":"2019","journal-title":"Hum. Genet."},{"issue":"2","key":"10.1016\/j.ejpn.2024.08.006_bib50","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcaa075","article-title":"Intragenic and structural variation in the SMN locus and clinical variability in spinal muscular atrophy","volume":"2","author":"Wadman","year":"2020","journal-title":"Brain Commun"},{"key":"10.1016\/j.ejpn.2024.08.006_bib51","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3389\/fneur.2019.00898","article-title":"Biomarkers and the development of a personalized medicine approach in spinal muscular atrophy","volume":"10","author":"Kariyawasam","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ejpn.2024.08.006_bib52","doi-asserted-by":"crossref","DOI":"10.1177\/11772719211035643","article-title":"Update on biomarkers in spinal muscular atrophy","volume":"16","author":"Pino","year":"2021","journal-title":"Biomark. Insights"}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379824001272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379824001272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T01:09:13Z","timestamp":1732928953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090379824001272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":52,"alternative-id":["S1090379824001272"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2024.08.006","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes for patients in the RESTORE registry with spinal muscular atrophy and four or more SMN2 gene copies treated with onasemnogene abeparvovec","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2024.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Paediatric Neurology Society.","name":"copyright","label":"Copyright"}]}}